Arctis Global’s Atara Biotherapeutics ATRA Stock Holding History

Arctis Global’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,882	Closed	-$588K	–	2
2023 Q3	$588K	Buy	+15,882	New	+$707K	0.32%	12

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arctis Global's ATRA Position: Q4 2023 in Review

Arctis Global sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 15,882 shares — an estimated $588K sold.

Arctis Global first reported a position in ATRA in Q3 2023 and held it in 1 quarter. The position peaked at $588K in Q3 2023. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

Arctis Global reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
Arctis Global sold 15,882 Atara Biotherapeutics shares in Q4 2023, an estimated $588K.
Arctis Global first reported a position in Atara Biotherapeutics in Q3 2023 and held it in 1 quarter.
Arctis Global's Atara Biotherapeutics position peaked at $588K in Q3 2023.
89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Arctis Global's 13F filing for Q4 2023, filed 14 Feb 2024.